

# Laura Godfrey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5373748/publications.pdf>

Version: 2024-02-01

8  
papers

516  
citations

1163117

8  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1139  
citing authors

#	ARTICLE	IF	CITATIONS
1	H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. <i>Leukemia</i> , 2021, 35, 90-106.	7.2	35
2	Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. <i>Cell Reports</i> , 2021, 35, 109101.	6.4	20
3	BET inhibition disrupts transcription but retains enhancer-promoter contact. <i>Nature Communications</i> , 2021, 12, 223.	12.8	84
4	Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. <i>Blood</i> , 2019, 134, 1059-1071.	1.4	62
5	DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation. <i>Nature Communications</i> , 2019, 10, 2803.	12.8	99
6	MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation. <i>Experimental Hematology</i> , 2017, 47, 64-75.	0.4	25
7	MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. <i>Cell Reports</i> , 2017, 18, 482-495.	6.4	69
8	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015, 13, 2715-2727.	6.4	118